

## S 2691

Opioid Crisis Accountability Act of 2018

**Congress:** 115 (2017–2019, Ended)

**Chamber:** Senate

**Policy Area:** Health

**Introduced:** Apr 17, 2018

**Current Status:** Read twice and referred to the Committee on Finance.

**Latest Action:** Read twice and referred to the Committee on Finance. (Apr 17, 2018)

**Official Text:** <https://www.congress.gov/bill/115th-congress/senate-bill/2691>

### Sponsor

**Name:** Sen. Sanders, Bernard [I-VT]

**Party:** Independent • **State:** VT • **Chamber:** Senate

### Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Sen. Harris, Kamala D. [D-CA]	D · CA		Apr 17, 2018
Sen. Blumenthal, Richard [D-CT]	D · CT		Apr 19, 2018
Sen. Gillibrand, Kirsten E. [D-NY]	D · NY		Apr 19, 2018

### Committee Activity

Committee	Chamber	Activity	Date
Finance Committee	Senate	Referred To	Apr 17, 2018

### Subjects & Policy Tags

**Policy Area:**

Health

### Related Bills

Bill	Relationship	Last Action
115 HR 5782	Identical bill	<b>May 31, 2018:</b> Referred to the Subcommittee on Health.

## **Opioid Crisis Accountability Act of 2018**

This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit a drug manufacturer from engaging in illegal marketing and distribution practices, including falsely advertising, promoting, or marketing that an opioid has no addiction-forming or addiction-sustaining qualities or risks.

The bill penalizes drug manufacturers or distributors who illegally advertise, market or distribute an opioid product, including by (1) imposing a civil fine or salary confiscation, (2) revoking any remaining period of market exclusivity for such product, (3) requiring reimbursement of federal funding received for such product, and (4) prohibiting certain tax credits.

## **Actions Timeline**

---

- **Apr 17, 2018:** Introduced in Senate
- **Apr 17, 2018:** Read twice and referred to the Committee on Finance.